A Phase 2 interventional study of VX-809 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 1st registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 93 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 48th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2009, is one of 21 in phase 2, and was the 2nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the safety and tolerability of VX-809 in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.
This was a Phase 2, randomized, double-blind, placebo-controlled, multiple-dose study of orally-administered VX-809 in participants with CF who are homozygous for the specific CFTR mutation known as ∆F508 or F508del. Enrollment was planned for 90 participants at approximately 20 centers. Participants were planned to be randomized in a 4:1 ratio to receive 1 of 4 doses of VX-809 or placebo once a day for 28 days in a parallel design. Participants were outpatients during the study, except for overnight stays on Day 1 and 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matched to VX-809 capsule orally once daily for 28 days.
Drug: Placebo
VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
Drug: VX-809
VX-809, 50 mg capsule orally once daily for 28 days.
Drug: VX-809
VX-809, 100 mg capsule orally once daily for 28 days.
Drug: VX-809
VX-809, 200 mg capsule orally once daily for 28 days.
Drug: VX-809
Capsules
Placebo matched to VX-809 capsules.
Safety and Tolerability Based on Adverse Events (AEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. An AE that started at or after initial dosing of study drug, or increased in severity after initial dosing of study drug visit is considered treatment-emergent.
Time frame: Up to 14 days after last dose (last dose = Day 28)
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 28
Change From Baseline in Percent Predicted FEV1 at Day 28
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Predicted FEV1 (for age, gender, and height) was calculated using the Knudson method.
Time frame: Baseline, Day 28
Change From Baseline in Forced Vital Capacity (FVC) at Day 28
FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
Time frame: Baseline, Day 28
Change From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28
FEF25-75 is total volume of air exhaled from the lungs over the middle half of the FVC test, expressed as liters per second (L/sec).
Time frame: Baseline, Day 28
Change From Baseline in Sweat Chloride at Day 28
Sweat samples were collected using an approved Macroduct (Wescor) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.
Time frame: Baseline, Day 28
Change From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28
Nasal potential difference (NPD) provides a direct and sensitive evaluation of sodium and chloride transport in secretory epithelial cells via assessment of transepithelial bioelectric properties. NPD under conditions of zero chloride concentration perfusion solution in the presence of isoproterenol is reported. NPDs were performed according to Cystic Fibrosis Foundation Therapeutics Development Network (CFFT TDN) Standard Operating Procedure (SOP) 528.00 "Standardization of Measurement of Nasal Membrane Transepithelial Potential Difference (NPD) - electronic data capture (EDC) and Perfusion or Perfusion-Free Probe".
Time frame: Baseline, Day 28
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Domain Scores at Day 28
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. CFQ-R domains include: Body, Digestion, Eat, Emotion, Health Perceptions, Physical, Respiratory, Role, Social, Treatment Burden, Vitality, and Weight. Individual domain score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Day 28
Maximum Plasma Concentration (Cmax) of VX-809
Only participants who received VX-809 were analyzed for this outcome measure.
Time frame: Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, 24, and 30-60 hours post dose)
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of VX-809
Only participants who received VX-809 were analyzed for this outcome measure.
Time frame: Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post dose)
| Milestone | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Started | 19 | 18 | 18 | 18 | 20 |
| Completed | 17 | 18 | 18 | 17 | 19 |
| Not completed | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Randomized but not treated | 2 | 0 | 0 | 1 | 1 |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. An AE that started at or after initial dosing of study drug, or increased in severity after initial dosing of study drug visit is considered treatment-emergent.
| participants | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Participants With Any AE | 17 | 16 | 15 | 16 | 18 |
| Participants With SAE | 1 | 5 | 1 | 0 | 3 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| liters | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28 | 0.029 (-0.0823 to 0.1398) | -0.049 (-0.1578 to 0.0588) | -0.031 (-0.1401 to 0.0787) | 0.015 (-0.0972 to 0.1263) | -0.009 (-0.1146 to 0.0970) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Predicted FEV1 (for age, gender, and height) was calculated using the Knudson method.
| Percent predicted of FEV1 | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Percent Predicted FEV1 at Day 28 | 0.285 (-2.8268 to 3.3973) | -1.637 (-4.6836 to 1.4089) | -0.375 (-3.4540 to 2.7046) | 0.168 (-2.9653 to 3.3011) | -0.165 (-3.1346 to 2.8044) |
FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
| liters | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Forced Vital Capacity (FVC) at Day 28 | 0.085 ± 0.2857 | -0.055 ± 0.2331 | -0.020 ± 0.3494 | -0.004 ± 0.1916 | -0.023 ± 0.3668 |
FEF25-75 is total volume of air exhaled from the lungs over the middle half of the FVC test, expressed as liters per second (L/sec).
| liters per second (L/sec) | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28 | -0.030 ± 0.1730 | -0.011 ± 0.3231 | -0.029 ± 0.4373 | 0.045 ± 0.2702 | -0.052 ± 0.3558 |
Sweat samples were collected using an approved Macroduct (Wescor) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.
| millimole per liter (mmol/L) | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Sweat Chloride at Day 28 | 0.84 (-3.493 to 5.166) | 0.93 (-3.308 to 5.173) | -3.77 (-7.966 to 0.416) | -5.29 (-9.618 to -0.963) | -7.38 (-11.590 to -3.166) |
Nasal potential difference (NPD) provides a direct and sensitive evaluation of sodium and chloride transport in secretory epithelial cells via assessment of transepithelial bioelectric properties. NPD under conditions of zero chloride concentration perfusion solution in the presence of isoproterenol is reported. NPDs were performed according to Cystic Fibrosis Foundation Therapeutics Development Network (CFFT TDN) Standard Operating Procedure (SOP) 528.00 "Standardization of Measurement of Nasal Membrane Transepithelial Potential Difference (NPD) - electronic data capture (EDC) and Perfusion or Perfusion-Free Probe".
| millivolts (mV) | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Change From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28 | -1.017 (-3.2979 to 1.2637) | 0.832 (-1.1302 to 2.7943) | 0.142 (-2.0369 to 2.3208) | 1.382 (-0.9853 to 3.7491) | 1.583 (-0.6952 to 3.8612) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. CFQ-R domains include: Body, Digestion, Eat, Emotion, Health Perceptions, Physical, Respiratory, Role, Social, Treatment Burden, Vitality, and Weight. Individual domain score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Body | -1.341 (-6.4183 to 3.7370) | -0.206 (-5.2276 to 4.8151) | -1.626 (-6.6796 to 3.4276) | 2.611 (-2.5525 to 7.7746) | 0.058 (-4.8954 to 5.0123) |
| Digestion | 4.620 (-0.2530 to 9.4935) | 2.284 (-2.4928 to 7.0605) | -0.719 (-5.5599 to 4.1216) | 0.251 (-4.6794 to 5.1810) | 2.578 (-2.1027 to 7.2580) |
| Eat | 2.110 (-3.9925 to 8.2128) | -3.662 (-9.6704 to 2.3463) | -7.269 (-13.3216 to -1.2161) | 3.242 (-3.0242 to 9.5087) | -2.576 (-8.4313 to 3.2793) |
| Emotion | 4.859 (-0.4200 to 10.1372) | -3.222 (-8.4312 to 1.9866) | -1.358 (-6.5817 to 3.8666) | 3.489 (-1.9312 to 8.9087) | -2.624 (-7.7058 to 2.4585) |
| Health Perceptions | 5.034 (-1.6041 to 11.6713) | -2.839 (-9.2912 to 3.6131) | -6.967 (-13.4203 to -0.5137) | -0.435 (-7.0778 to 6.2074) | -1.896 (-8.3524 to 4.5604) |
| Physical | 1.225 (-5.3271 to 7.7764) | -5.968 (-12.3586 to 0.4217) | -7.384 (-13.8167 to -0.9508) | -3.464 (-10.0613 to 3.1335) | -0.976 (-7.2596 to 5.3067) |
| Respiratory | 4.534 (-1.6158 to 10.6842) | -5.223 (-11.2414 to 0.7956) | -6.324 (-12.3453 to -0.3026) | -1.290 (-7.5407 to 4.9598) | 2.215 (-3.6610 to 8.0901) |
| Role | 2.210 (-3.2279 to 7.6481) | -5.941 (-11.3247 to -0.5577) | -4.599 (-9.9912 to 0.7925) | 1.097 (-4.4579 to 6.6510) | -6.533 (-11.7858 to -1.2803) |
| Social | -0.554 (-4.8235 to 3.7152) | -0.001 (-4.2221 to 4.2200) | -1.013 (-5.2372 to 3.2122) | 0.469 (-3.8898 to 4.8273) | -2.640 (-6.7802 to 1.5008) |
| Treatment Burden | 2.463 (-3.1916 to 8.1169) | 4.185 (-1.4220 to 9.7914) | -5.962 (-11.5712 to -0.3530) | 1.421 (-4.3528 to 7.1954) | -0.676 (-6.1363 to 4.7843) |
| Vitality | -2.178 (-8.8193 to 4.4629) | -4.645 (-11.1048 to 1.8139) | -7.227 (-13.6961 to -0.7589) | -1.516 (-8.1800 to 5.1472) | 0.730 (-5.5932 to 7.0522) |
| Weight | 0.304 (-9.4460 to 10.0543) | 5.410 (-4.2393 to 15.0600) | 2.175 (-7.5500 to 11.8997) | 8.827 (-1.1524 to 18.8063) | -4.186 (-13.5956 to 5.2233) |
Only participants who received VX-809 were analyzed for this outcome measure.
| nanogram per milliliter (ng/mL) | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|
| Day 1 (n= 18, 18, 17, 19) | 760 ± 280 | 1850 ± 697 | 2930 ± 916 | 6410 ± 2550 |
| Day 28 (n= 17, 17, 16, 18) | 1100 ± 443 | 2660 ± 1010 | 4620 ± 1840 | 10300 ± 4490 |
Only participants who received VX-809 were analyzed for this outcome measure.
| hour*nanogram per milliliter (hr*ng/mL) | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|
| Day 1 (n= 18, 18, 17, 19) | 7190 ± 2190 | 16600 ± 6290 | 29000 ± 11400 | 59500 ± 26400 |
| Day 28 (n= 17, 17, 16, 18) | 12900 ± 4920 | 28800 ± 13100 | 54100 ± 31600 | 119000 ± 73700 |
Collected over Up to 14 days after last dose (last dose = Day 28). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/17 (5.9%) | 17/17 (100%) |
| VX-809, 25 mg | — | 5/18 (27.8%) | 16/18 (88.9%) |
| VX-809, 50 mg | — | 1/18 (5.6%) | 15/18 (83.3%) |
| VX-809, 100 mg | — | 0/17 (0%) | 16/17 (94.1%) |
| VX-809, 200 mg | — | 3/19 (15.8%) | 18/19 (94.7%) |
| Event | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| Cystic fibrosis lungCongenital, familial and genetic disorders | 1/17 | 4/18 | 1/18 | 0/17 | 3/19 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/17 | 1/18 | 0/18 | 0/17 | 0/19 |
| Event | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 7/17 | 10/18 | 6/18 | 7/17 | 10/19 |
| RalesRespiratory, thoracic and mediastinal disorders | 1/17 | 6/18 | 2/18 | 3/17 | 3/19 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 3/17 | 2/18 | 0/18 | 4/17 | 6/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/17 | 5/18 | 3/18 | 2/17 | 4/19 |
| HeadacheNervous system disorders | 3/17 | 4/18 | 5/18 | 2/17 | 5/19 |
| PyrexiaGeneral disorders | 2/17 | 2/18 | 1/18 | 1/17 | 5/19 |
| WheezingRespiratory, thoracic and mediastinal disorders | 3/17 | 1/18 | 4/18 | 1/17 | 0/19 |
| Respiration abnormalRespiratory, thoracic and mediastinal disorders | 0/17 | 1/18 | 1/18 | 0/17 | 4/19 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/17 | 2/18 | 1/18 | 2/17 | 2/19 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/17 | 0/18 | 3/18 | 0/17 | 2/19 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 31.5 ± 9.35 | 27.7 ± 8.98 | 27.1 ± 8.20 | 30.1 ± 11.55 | 26.7 ± 6.82 | 28.6 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo | VX-809, 25 mg | VX-809, 50 mg | VX-809, 100 mg | VX-809, 200 mg | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 9 | 9 | 5 | 7 | 36 |
| Male | 11 | 9 | 9 | 12 | 12 | 53 |
The record gives a start of Mar 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 5 years 8 months after primary completion. A results delay was requested in Mar 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumacaftor
Vertex Pharmaceuticals Incorporated →